MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study

The Lancet Oncology

Volumn 9, Issue 9, 2008, Pages 850-856

  Heesakkers, Roel AM ^a   Hövels, Anke M ^a   Jager, Gerrit J ^c   van den Bosch, Harrie CM ^b   Witjes, J Alfred ^a   Raat, Hein PJ ^f   Severens, Johan L ^d,e   Adang, Eddy MM ^a   van der Kaa, Christina Hulsbergen ^a   Fütterer, Jurgen J ^a   Barentsz, Jelle ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Department of Radiology Zorgsaam Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NONIONIC CONTRAST MEDIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG INDUCED HEADACHE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE PAIN; INTERMETHOD COMPARISON; LOW BACK PAIN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NETHERLANDS; NOMOGRAM; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; SENSITIVITY AND SPECIFICITY; URTICARIA;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; ECHO-PLANAR IMAGING; HUMANS; IRON; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OXIDES; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 49949101872     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70203-1     Document Type: Article

References (38)

1. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
2. Wolf Jr. J.S., Cher M., Dall'era M., Presti Jr. J.C., Hricak H., and Carroll P.R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153 (1995) 993-999
3. Hövels A.M., Heesakkers R.A., Adang E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63 (2008) 387-395
4. Borley N., Fabrin K., Sriprasad S., et al. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37 (2003) 382-386
5. Jager G.J., Barentsz J.O., Oosterhof G.O., Witjes J.A., and Ruijs S.J. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167 (1996) 1503-1507
6. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
7. Kattan M.W. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005. Eur Urol 52 (2007) 1528
8. Narayan P., Fournier G., Gajendran V., et al. Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 44 (1994) 519-524
9. Bishoff J.T., Reyes A., Thompson I.M., et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 45 (1995) 270-274
10. Bluestein D.L., Bostwick D.G., Bergstralh E.J., and Oesterling J.E. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 151 (1994) 1315-1320
11. El Galley R.E., Keane T.E., Petros J.A., et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 52 (1998) 663-667
12. Meng M.V., and Carroll P.R. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 164 (2000) 1235-1240
13. Will O., Purkayastha S., Chan C., et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7 (2006) 52-60
14. Bellin M.F., Roy C., Kinkel K., et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 207 (1998) 799-808
15. Bellin M.F., Lebleu L., and Meric J.B. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging 28 (2003) 155-163
16. Deserno W.M., Harisinghani M.G., Taupitz M., et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233 (2004) 449-456
17. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
18. Rockall A.G., Sohaib S.A., Harisinghani M.G., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 23 (2005) 2813-2821
19. Bellin M.F., Zaim S., Auberton E., et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193 (1994) 657-663
20. McLachlan S.J., Morris M.R., Lucas M.A., et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4 (1994) 301-307
21. Anzai Y., Blackwell K.E., Hirschowitz S.L., et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 192 (1994) 709-715
22. Anzai Y., McLachlan S., Morris M., Saxton R., and Lufkin R.B. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR Am J Neuroradiol 15 (1994) 87-94
23. Rorvik J., Halvorsen O.J., Albrektsen G., and Haukaas S. Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. Scand J Urol Nephrol 32 (1998) 116-119
24. Sawczuk I.S., deVere W.R., Gold R.P., and Olsson C.A. Sensitivity of computed tomography in evaluation of pelvic lymph node metastases from carcinoma of bladder and prostate. Urology 21 (1983) 81-84
25. Tiguert R., Gheiler E.L., Tefilli M.V., et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 53 (1999) 367-371
26. Triller J., and Fuchs W.A. Computed tomographic staging of prostatic cancer. Rofo 137 (1982) 669-674
27. Dooms G.C., Hricak H., Crooks L.E., and Higgins C.B. Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 153 (1984) 719-728
28. Lee J.K., Heiken J.P., Ling D., et al. Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. Radiology 153 (1984) 181-188
29. Oyen R.H., Van Poppel H.P., Ameye F.E., Van de Voorde W.A., Baert A.L., and Baert L.V. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190 (1994) 315-322
30. Harisinghani M.G., Saksena M., Ross R.W., et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66 (2005) 1066-1071
31. Mack M.G., Balzer J.O., Straub R., Eichler K., and Vogl T.J. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 222 (2002) 239-244
32. Michel S.C., Keller T.M., Frohlich J.M., et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225 (2002) 527-536
33. Tabatabaei S., Harisinghani M., and McDougal W.S. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol 174 (2005) 923-927
34. El Galley R.E., Keane T.E., Petros J.A., et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 52 (1998) 663-667
35. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Radiology 226 (2003) 24-28
36. Burkhard F.C., Schumacher M., and Studer U.H. The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol 2 (2005) 336-342
37. Miyake H., Hara I., Kurashi T., Inoue T.A., Eto H., and Fujisawa M. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13 (2007) 1192-1197
38. Schostak M., Krause H., Miller K., Schrader M., Kempkensteffen C., and Kollermann J. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years. BJU Int 99 (2007) 1404-1414